Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A network approach to developing immuno-oncology combinations in Canada.

Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S.

Curr Oncol. 2019 Apr;26(2):73-79. doi: 10.3747/co.26.4393. Epub 2019 Apr 1.

2.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
3.

Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.

Force J, Leal JHS, McArthur HL.

Curr Treat Options Oncol. 2019 Mar 28;20(4):35. doi: 10.1007/s11864-019-0634-5. Review.

PMID:
30923913
4.

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer.

Basho RK, McArthur HL.

Ther Adv Med Oncol. 2018 Jun 24;10:1758835918775697. doi: 10.1177/1758835918775697. eCollection 2018. Review.

5.

Immunotherapy in Breast Cancer: the New Frontier.

Hu ZI, McArthur HL.

Curr Breast Cancer Rep. 2018;10(2):35-40. doi: 10.1007/s12609-018-0274-y. Epub 2018 Apr 16. Review.

6.

Innovations and Challenges in the Treatment of Metastatic Triple-Negative Breast Cancer.

McArthur HL.

J Oncol Pract. 2018 May;14(5):290-291. doi: 10.1200/JOP.18.00224. No abstract available.

PMID:
29746806
7.

Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD.

Clin Breast Cancer. 2018 Oct;18(5):353-361. doi: 10.1016/j.clbc.2017.12.009. Epub 2017 Dec 21.

PMID:
29337140
8.

Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.

Page DB, Wen H, Brogi E, Dure D, Ross D, Spinelli KJ, Patil S, Norton L, Hudis C, McArthur HL.

Breast Cancer Res Treat. 2018 Jan;167(2):547-554. doi: 10.1007/s10549-017-4520-1. Epub 2017 Oct 6.

PMID:
28986743
9.

Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.

Hu ZI, Ho AY, McArthur HL.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029. Epub 2017 May 26. Review.

PMID:
28816141
10.

Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.

Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, McArthur HL, Gönen M, Dickler M, Weber WA.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1428-1437. doi: 10.1007/s00259-017-3703-7. Epub 2017 May 1.

11.

The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?

Hu ZI, McArthur HL, Ho AY.

Curr Breast Cancer Rep. 2017;9(1):45-51. doi: 10.1007/s12609-017-0234-y. Epub 2017 Mar 2. Review.

12.
13.

Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.

Sanchez K, Page D, McArthur HL.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):151-162. doi: 10.1016/j.currproblcancer.2016.09.009. Epub 2016 Sep 26. Review.

PMID:
27855963
14.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.

15.

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.

Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL.

Clin Breast Cancer. 2016 Dec;16(6):487-493. doi: 10.1016/j.clbc.2016.07.013. Epub 2016 Aug 1.

16.

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.

Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL.

Cancer Immunol Res. 2016 Oct;4(10):835-844. Epub 2016 Sep 1. Erratum in: Cancer Immunol Res. 2017 Mar;5(3):269.

17.

Checkpoint inhibitors in breast cancer: hype or promise?

McArthur HL.

Clin Adv Hematol Oncol. 2016 Jun;14(6):392-5. No abstract available.

PMID:
27379806
18.

Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients.

Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, Weber WA.

Am J Nucl Med Mol Imaging. 2016 Apr 24;6(2):120-7. eCollection 2016.

19.

The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.

Lanning RM, Morrow M, Riaz N, McArthur HL, Dang C, Moo TA, El-Tamer M, Krause K, Siu C, Hsu M, Zhang Z, Pei X, McCormick B, Powell SN, Ho A.

Ann Surg Oncol. 2015 Aug;22(8):2517-25. doi: 10.1245/s10434-014-4321-2. Epub 2015 Jan 7.

PMID:
25564167
20.

Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.

McArthur HL, Morris PG, Hudis CA.

J Clin Oncol. 2015 Jan 1;33(1):124-5. doi: 10.1200/JCO.2014.58.2965. Epub 2014 Nov 17. No abstract available.

PMID:
25403210
21.

Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.

Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL.

J Hum Nutr Diet. 2015 Jun;28(3):272-82. doi: 10.1111/jhn.12229. Epub 2014 Mar 19.

22.

Emerging immunotherapy strategies in breast cancer.

Page DB, Naidoo J, McArthur HL.

Immunotherapy. 2014;6(2):195-209. doi: 10.2217/imt.13.166. Review.

PMID:
24491092
23.

Trastuzumab and chemotherapy may be appropriate for small, node-negative, HER2-positive breast cancer.

Morris PG, McArthur HL.

Oncologist. 2012;17(10):e33; author reply e34. doi: 10.1634/theoncologist.2012-0318. No abstract available.

24.

Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.

Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL.

Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54. doi: 10.1158/1940-6207.CAPR-12-0117. Epub 2012 Jul 24.

25.

Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.

Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, Larson S, Hudis CA, McArthur HL, Jochelson MS.

Cancer. 2012 Nov 15;118(22):5454-62. doi: 10.1002/cncr.27579. Epub 2012 Apr 19.

26.

Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.

Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.

Cancer. 2012 Apr 15;118(8):1982-8. doi: 10.1002/cncr.26484. Epub 2011 Sep 1.

27.

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.

McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.

Cancer. 2011 Dec 15;117(24):5461-8. doi: 10.1002/cncr.26171. Epub 2011 Jun 16.

28.

Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.

Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT.

Clin Cancer Res. 2011 May 15;17(10):3490-9. doi: 10.1158/1078-0432.CCR-10-1359. Epub 2011 Mar 3.

29.

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN.

Clin Cancer Res. 2011 May 15;17(10):3398-407. doi: 10.1158/1078-0432.CCR-10-1969. Epub 2011 Feb 24.

30.

Aromatase inhibitor strategies in metastatic breast cancer.

McArthur HL, Morris PG.

Int J Womens Health. 2010 Aug 9;1:67-72.

31.

Chemotherapy: Neoadjuvant trial design: time for a brave new world?

McArthur HL, Hudis CA.

Nat Rev Clin Oncol. 2010 Jul;7(7):359-60. doi: 10.1038/nrclinonc.2010.85. No abstract available.

PMID:
20592708
32.

Update on administration of adjuvant trastuzumab.

McArthur HL.

Clin Adv Hematol Oncol. 2010 May;8(5):321-2, 375. No abstract available.

PMID:
20551890
33.

Dose-dense chemotherapy for breast cancer: what does the future hold?

Morris PG, McArthur HL, Hudis C, Norton L.

Future Oncol. 2010 Jun;6(6):951-65. doi: 10.2217/fon.10.59. Review.

PMID:
20528233
34.

Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.

Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, Dickler M, Hudis CA, Jochelson M, McArthur HL.

J Clin Oncol. 2010 Jul 1;28(19):3154-9. doi: 10.1200/JCO.2009.27.5743. Epub 2010 Jun 1.

35.

Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.

Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT.

J Clin Oncol. 2009 Dec 20;27(36):6117-23. doi: 10.1200/JCO.2008.20.2952. Epub 2009 Nov 9.

36.

Trastuzumab: a picky partner?

McArthur HL, Hudis CA.

Clin Cancer Res. 2009 Oct 15;15(20):6311-3. doi: 10.1158/1078-0432.CCR-09-1917. Epub 2009 Oct 13.

37.

Therapeutic options for metastatic breast cancer.

Morris PG, McArthur HL, Hudis CA.

Expert Opin Pharmacother. 2009 Apr;10(6):967-81. doi: 10.1517/14656560902834961 . Review.

PMID:
19351274
38.

Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.

McArthur HL, Gelmon KA, Olivotto IA, Speers CH, Ellard SL, O'Reilly SE, Kennecke HF.

J Clin Oncol. 2009 Mar 20;27(9):1388-93. doi: 10.1200/JCO.2008.18.4127. Epub 2009 Feb 23.

PMID:
19237634
39.

Biomarkers in breast cancer.

McArthur HL, Dickler MN.

Cancer Biol Ther. 2008 Jan;7(1):21-2. Epub 2008 Feb 11. No abstract available.

PMID:
18347421
40.

Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data.

McArthur HL, Hudis CA.

Clin Breast Cancer. 2007 Dec;8 Suppl 1:S6-S10. Review.

PMID:
18282369
41.

Advances in adjuvant chemotherapy of early stage breast cancer.

McArthur HL, Hudis CA.

Cancer Treat Res. 2008;141:37-53. Review. No abstract available.

PMID:
18274081
42.

Has first-line therapy had an impact on general outcome in metastatic breast cancer?

McArthur HL, Hudis CA.

Future Oncol. 2007 Aug;3(4):411-8. Review.

PMID:
17661716
43.

Breast cancer chemotherapy.

McArthur HL, Hudis CA.

Cancer J. 2007 May-Jun;13(3):141-7. Review.

PMID:
17620762
44.

Cardiotoxicity of trastuzumab in clinical practice.

McArthur HL, Chia S.

N Engl J Med. 2007 Jul 5;357(1):94-5. No abstract available.

PMID:
17611218
45.

Adjuvant chemotherapy for early-stage breast cancer.

McArthur HL, Hudis CA.

Hematol Oncol Clin North Am. 2007 Apr;21(2):207-22. Review.

PMID:
17512445
46.

Intravascular hemolysis as a complication of clostridium perfringens sepsis.

McArthur HL, Dalal BI, Kollmannsberger C.

J Clin Oncol. 2006 May 20;24(15):2387-8. No abstract available.

PMID:
16710038

Supplemental Content

Loading ...
Support Center